New perspectives: Role of sunitinib in breast cancer

Clinica Terapeutica

Volumn 161, Issue 5, 2010, Pages 475-482

  Fratto, M E ^a   Imperatori, M ^a   Vincenzi, B ^a   Tomao, F ^b   Santini, D ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast cancer; Clinical trials; Preclinical evidences; Sunitinib

Indexed keywords

SUNITINIB;

BREAST CANCER; BREAST METASTASIS; CLINICAL TRIAL; DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INDOLES; NEOPLASM METASTASIS; PYRROLES;

EID: 78149318043     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Goodman VL, Rock EP, Dagher R, et. al. Clin Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Cancer Res 2007; 13:1367-73
2. Mendel DB, Laird AD, Xin X, Louie SG et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-37
3. Abrams TJ, Lee LB, Murray LJ, Pryer NK et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471-8
4. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20:757-66
5. Patyna S, Arrigoni C, Terron A, et al. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 2008; 36:905-16
6. Yang F, Jove V, Xin H, et al. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 2010; 8:35-45
7. O'Farrell AM, Abrams TJ, Yuen HA. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-605
8. Davis DW et al. Receptor Tyrosine kinase activity and apoptosis in gastrointestinal stromal tumors: a pharmaco-dynamic analysis of response to sunitinib malate (SU112248). ABSTRACT No. A253. 17th AACR-NCI-EORTC International conference on molecular targets and cancer therapeutics. 2005
9. Deprimo SE, Huang X, Blackstein ME, et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res 2009; 15:5869-77
10. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25-35 (Pubitemid 46630490)
11. Suppiah R, Finke J, Rini BI et al. T regulatory cells (Treg) in patients with mRCC decrease during sunitinib treatment: correlation with clinical responses and T helper 1\T helper 2 bias. JCO 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 24, Abstract No 2526
12. Pfizer. Sutent online prescribing information available on line on www.pfizer.com/products/rx/rx-product-sutent.jsp
13. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-38
14. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356:115-24 (Pubitemid 46089672)
15. Vascular endothelial growth factor. Ferrara N. Arterioscler Thromb Vasc Biol 2009; 29:789-91
16. Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/ Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 2002; 33:863-70
17. Meunier-Carpentier S, Dales JP, Djemli A, et al. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 2005; 26:977-84
18. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 1998; 184:53-7
19. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76
20. Valtola R, Salven P, Heikkilä P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154:1381-90 (Pubitemid 29226433)
21. Ariad S, Seymour L, Bezwoda WR. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat 1991; 20:11-7
22. Seymour L, Dajee D, Bezwoda WR Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 1993; 26:247-52 (Pubitemid 23304240)
23. Carvalho S, e Silva AO, Milanezi F, et al. c-KIT and PDG-FRA in breast phyllodes tumours: overexpression without mutations? J Clin Pathol 2004; 57:1075-9
24. Roussidis AE, Theocharis AD, Tzanakakis GN, Karamanos NK. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr Med Chem 2007; 14:735-43
25. Kluger HM, Dolled-Filhart M, Rodov S, et al. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 2004; 10:173-7 (Pubitemid 38114176)
26. Maher MG, Sapi E, Turner B, et al. Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin Cancer Res 1998; 4:1851-6
27. Coltrera MD, Wang J, Porter PL, Gown AM. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 1995; 55:2703-8
28. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2:1011-21
29. Liljegren A, Bergh J, Castany R. Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast 2009; 18:259-62
30. Kozloff M, Chuang E, Roy J, et al. A phase I study of Sunitinib plus paclitaxel for first-line treatment of advanced breast cancer: preliminary results. Presented at: San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Tex. Abstract 6078
31. Gianni L, Cardoso F, Mariani G, et al. Exploratory evaluation of sequential administration of docetaxel and sunitinib in women with advanced breast cancer. Presented at: San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Tex. Abstract 6079
32. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 10, 26:1810-6
33. Wildiers H, Fontaine C, Vuylsteke P, et al. SUCON Trial (SUnitinib CONsolidation Therapy in Metastatic Breast Cancer): A Belgian Multicenter Phase II Randomized Trial in Her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy with Sunitinib after Objective Response to Taxane Chemotherapy. Proceedings of the San Antonio Breast Cancer Symposium 2009; Abstr. 203
34. Mayer E, Kozloff M, Qamar R, et al SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as firstline treatment for HER2-negative metastatic breast cancer (MBC): final results. Cancer Res 2009; 69:Abstr 3126
35. http://mediaroom.pfizer.com/portal/site/pfizer/?ndmViewId= news-view&newsId=20090402005273&newsLang-en
36. http://www.fiercebiotech.com/press-releases/pfizer-discontinues-sun-1094- trial-sunitinib-plus-paclitaxel-ad vanced-breast-cancer
37. http://clinicaltrials.gov/ct2/show/results/NCT00393939
38. https://www.suntrials.com/breast-cancer-trials.aspx
39. http://clinicaltrials.gov/ct2/show/NCT00616122?term=NCT 00616122&rank=1
40. http://clinicaltrials.gov/ct2/show/NCT00905021?term= sunitinib+exemestane&rank=3
41. http://clinicaltrials.gov/ct2/show/NCT00931450?term=NCT 00931450&rank=1
42. http://clinicaltrials.gov/ct2/results?term=NCT00887575
43. Slade MJ, Payne R, Riethdorf S, et al. Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer 2009; 100:160-6
44. http://clinicaltrials.gov/ct2/results?term=NCT00824538
45. Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer 2006; 13:905-19
46. Tien Hoang, Shyh-Min Huang, Eric Armstrong and Paul M. Harari Augmentation of radiation response with the VEGFR- tyrosine kinase inhibitor ZD6474 et al. Proc Amer Assoc Cancer Res, 2004 available at: www.aacrmeetingabstracts. org/cgi/content/abstract/2004/1/955-b
47. Jones SM, Klinghoffer R, Prestwich GD, Toker A, et. Al. PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1. Curr Biol 1999; 9:512-21